



Statement

With the development of the pandemic, new variants of the SARS-CoV-2 have been reported all over the world.

For the effective control of the pandemic, rapid and accurate screening of the target SARS-CoV-2 including the new occurred variants is of great significance.

Currently, the new variant, which is defined as Omicron (B.1.1.529), has been found in South Africa.

The variant sites of B.1.1.529 located main in the Spike proteins of SARS-CoV-2. According to the research, among the 50 variant sites, there are more than 30 variant sites located in the Spike protein, which induce 43 amino acid mutated residues in the Spike protein. Meanwhile, there are also some variant sites to the N protein. And these variant sites in N protein are not in the critical sites.

The detection target of the DEEPBLUE COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) is the N protein of SARS-CoV-2. The recognition site of our Antigen Test Kit locates in the site 45-187 of N protein. The new occurred variant Omicron of SARS-CoV-2 will not affect the screen results of the kit. The detection performance of our COVID-19 (SARS-CoV-2) Antigen Test Kit including the sensitivity and specificity can be well guaranteed. And we will also continue pay attention to the variants of the SARS-CoV-2 and make the update on the website.

Anhui DeepBlue Medical Technology Co. Ltd.

30/11/2021

30/11/2021

安徽深蓝医疗科技股份有限公司
ANHUI DEEPBLUE MEDICAL TECHNOLOGY CO.,LTD.